Hoffmann-La Roche Inc Patent Portfolio Statistics

tip_user1

Hoffmann-La Roche Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Hoffmann-La Roche Inc. look like?

Assignee Art Units
Total Applications: 2,490 1,731,173
Granted Patents: 1,496 908,189
Grant Index 72.34% ↑ 67.19%
Abandoned/Rejected Applications: 572 (27.66%) 443,528 (32.81%)
In-Process Applications: 420 379,456
Average Grant Time: 2.39 Years ↓ 2.74 Years
Average Office Actions: 1.32 ↓ 1.67

Which Technology Area Hoffmann-La Roche Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 307
1626 Organic Chemistry 274
1625 Organic Chemistry 258
1643 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 150
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 85

How many patents are Hoffmann-La Roche Inc. filing every year?

Year Total Applications Predicted
2022 0* 735
2021 22* 737
2020 103 539
2019 91 91
2018 138 –
2017 104 –
2016 131 –
2015 152 –
2014 117 –
2013 120 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Hoffmann-La Roche Inc. in USPTO?

Publication number: US20220074928A1
Application number: 17/525,187

Abstract:
Herein is reported a method for the determination of a bispecific antibody in a serum-containing sample comprising the steps of first incubating a solid phase to which a capture antibody specifically binding to the bispecific antibody has been immobilized with the sample to form an immobilized capture antibody-bispecific antibody-complex, thereafter incubating the solid phase with a replacement antibody that competes with the capture antibody for binding to the bispecific antibody and thereby forming a solution comprising a replacement antibody-bispecific antibody-complex, and determining in the solution the replacement antibody-bispecific antibody-complex.

Publication date: 2022-03-10
Applicant: Hoffmann-La Roche Inc.
Inventors: Gregor Jordan

Publication number: US20220054635A1
Application number: 17/519,790

Abstract:
The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.

Publication date: 2022-02-24
Applicant: Hoffmann-La Roche Inc.
Inventors: Bacac Marina

Publication number: US20220033526A1
Application number: 17/507,511

Abstract:
The present invention relates to a set of heterodimeric polypeptides and its uses in therapy, e.g. for treating cancer.

Publication date: 2022-02-03
Applicant: Hoffmann-La Roche Inc.
Inventors: Dickopf Steffen

How are Hoffmann-La Roche Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/525,187 Interference-Suppressed Pharmacokinetic Immunoassay Docketed New Case – Ready for Examination OPAP Central, Docket
17/519,790 Treatment Method Expressly Abandoned — During Examination OPAP Central, Docket
17/507,511 Activatable Therapeutic Multispecific Polypeptides With Extended Half-Life Docketed New Case – Ready for Examination OPAP Central, Docket
17/507,029 Therapeutic Multispecific Polypeptides Activated By Polypeptide Chain Exchange – OPAP Central, Docket
17/506,993 Generation Of Antibody-Derived Polypeptides By Polypeptide Chain Exchange Docketed New Case – Ready for Examination OPAP Central, Docket